SQZ Biotechnologies Co: Nasdaq/NYSE listing notice — SQZ Biotechnologies receives NYSE delisting notice; reverse split deferred

SQZ Biotechnologies Co

NYSE notified SQZ on July 3 of delisting for average global market cap below $15M over 30 trading days.
Company will not appeal; trading suspended after July 3 close. Stock begins OTC trading on July 5.
OTC markets may offer less liquidity and could further depress stock price; no assurance of continued trading.
Reverse stock split, previously set for July 6, deferred to an undetermined later date.

item 3.01 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

SQZ Biotechnologies Co received a nyse delisting notice notice regarding market value (rules 802.01B).

Exchange: nyse
Notice: delisting notice
Deficiency: market value
Rules: 802.01B

Exact text from the filing

July 3, 2023, SQZ Biotechnologies Company (the “Company”) received a written notice from the New York Stock Exchange (“NYSE”) notifying the Company that the NYSE will commence proceedings to delist the Company’s common stock (“Common Stock”) from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization of at least $15 million over a consecutive 30-trading day period. The NYSE will apply to

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-031345

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.